Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial.

Fleischer DM, Burks AW, Vickery BP, Scurlock AM, Wood RA, Jones SM, Sicherer SH, Liu AH, Stablein D, Henning AK, Mayer L, Lindblad R, Plaut M, Sampson HA; Consortium of Food Allergy Research (CoFAR)..

J Allergy Clin Immunol. 2013 Jan;131(1):119-27.e1-7. doi: 10.1016/j.jaci.2012.11.011.

2.

Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial.

Burks AW, Wood RA, Jones SM, Sicherer SH, Fleischer DM, Scurlock AM, Vickery BP, Liu AH, Henning AK, Lindblad R, Dawson P, Plaut M, Sampson HA; Consortium of Food Allergy Research..

J Allergy Clin Immunol. 2015 May;135(5):1240-8.e1-3. doi: 10.1016/j.jaci.2014.12.1917.

3.

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.

Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG, Wood RA.

J Allergy Clin Immunol. 2015 May;135(5):1275-82.e1-6. doi: 10.1016/j.jaci.2014.11.005.

4.

Allergen-specific oral immunotherapy for peanut allergy.

Nurmatov U, Venderbosch I, Devereux G, Simons FE, Sheikh A.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009014. doi: 10.1002/14651858.CD009014.pub2. Review.

PMID:
22972130
5.

Efficacy of allergen-specific immunotherapy for peanut allergy: a meta-analysis of randomized controlled trials.

Sun J, Hui X, Ying W, Liu D, Wang X.

Allergy Asthma Proc. 2014 Mar-Apr;35(2):171-7. doi: 10.2500/aap.2014.35.3730.

PMID:
24717795
6.

Suppression of the immunologic response to peanut during immunotherapy is often transient.

Gorelik M, Narisety SD, Guerrerio AL, Chichester KL, Keet CA, Bieneman AP, Hamilton RG, Wood RA, Schroeder JT, Frischmeyer-Guerrerio PA.

J Allergy Clin Immunol. 2015 May;135(5):1283-92. doi: 10.1016/j.jaci.2014.11.010.

7.

Peanut oral immunotherapy in adolescents: study protocol for a randomized controlled trial.

Michaud E, Evrard B, Pereira B, Rochette E, Bernard L, Rouzaire PO, Gourdon-Dubois N, Merlin E, Fauquert JL.

Trials. 2015 Apr 29;16:197. doi: 10.1186/s13063-015-0717-y.

8.

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy.

Kulis M, Saba K, Kim EH, Bird JA, Kamilaris N, Vickery BP, Staats H, Burks AW.

J Allergy Clin Immunol. 2012 Apr;129(4):1159-62. doi: 10.1016/j.jaci.2011.11.045. No abstract available.

9.

Utility of component analyses in subjects undergoing sublingual immunotherapy for peanut allergy.

Burk CM, Kulis M, Leung N, Kim EH, Burks AW, Vickery BP.

Clin Exp Allergy. 2016 Feb;46(2):347-53. doi: 10.1111/cea.12635.

PMID:
26362760
10.

A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients.

Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT.

J Allergy Clin Immunol. 2013 Dec;132(6):1368-74. doi: 10.1016/j.jaci.2013.09.046.

11.

Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).

Syed A, Garcia MA, Lyu SC, Bucayu R, Kohli A, Ishida S, Berglund JP, Tsai M, Maecker H, O'Riordan G, Galli SJ, Nadeau KC.

J Allergy Clin Immunol. 2014 Feb;133(2):500-10. doi: 10.1016/j.jaci.2013.12.1037.

12.

Administration of a probiotic with peanut oral immunotherapy: A randomized trial.

Tang ML, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, Licciardi P, Burks W, Donath S.

J Allergy Clin Immunol. 2015 Mar;135(3):737-44.e8. doi: 10.1016/j.jaci.2014.11.034.

PMID:
25592987
13.

Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization.

Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W, Steele P, Kamilaris J, Vickery B, Burks AW.

J Allergy Clin Immunol. 2011 Mar;127(3):640-6.e1. doi: 10.1016/j.jaci.2010.12.1083.

14.

A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response.

Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, Hiegel A, Kamilaris J, Carlisle S, Yue X, Kulis M, Pons L, Vickery B, Burks AW.

J Allergy Clin Immunol. 2011 Mar;127(3):654-60. doi: 10.1016/j.jaci.2010.12.1111.

15.

Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.

Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, Burk C, Hiegel A, Carlisle S, Christie L, Perry TT, Pesek RD, Sheikh S, Virkud Y, Smith PB, Shamji MH, Durham SR, Jones SM, Burks AW.

J Allergy Clin Immunol. 2014 Feb;133(2):468-75. doi: 10.1016/j.jaci.2013.11.007.

16.

Clinical efficacy and immune regulation with peanut oral immunotherapy.

Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, Shreffler WG, Steele P, Henry KA, Adair M, Francis JM, Durham S, Vickery BP, Zhong X, Burks AW.

J Allergy Clin Immunol. 2009 Aug;124(2):292-300, 300.e1-97. doi: 10.1016/j.jaci.2009.05.022.

17.

Distinct parameters of the basophil activation test reflect the severity and threshold of allergic reactions to peanut.

Santos AF, Du Toit G, Douiri A, Radulovic S, Stephens A, Turcanu V, Lack G.

J Allergy Clin Immunol. 2015 Jan;135(1):179-86. doi: 10.1016/j.jaci.2014.09.001.

18.

The safety of peanut oral immunotherapy in peanut-allergic subjects in a single-center trial.

Yu GP, Weldon B, Neale-May S, Nadeau KC.

Int Arch Allergy Immunol. 2012;159(2):179-82. doi: 10.1159/000336391.

19.

Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens.

Vickery BP, Lin J, Kulis M, Fu Z, Steele PH, Jones SM, Scurlock AM, Gimenez G, Bardina L, Sampson HA, Burks AW.

J Allergy Clin Immunol. 2013 Jan;131(1):128-34.e1-3. doi: 10.1016/j.jaci.2012.10.048.

20.

The safety and efficacy of sublingual and oral immunotherapy for milk allergy.

Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S, Steele P, Driggers S, Burks AW, Wood RA.

J Allergy Clin Immunol. 2012 Feb;129(2):448-55, 455.e1-5. doi: 10.1016/j.jaci.2011.10.023.

Items per page

Supplemental Content

Support Center